Johnson & Johnson (JNJ) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal second quarter ended June 29, 2025, and the fiscal six months ended on the same date. Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The period was significantly impacted by major strategic acquisitions, including Intra-Cellular Therapies (April 2025) and Shockwave Medical (May 2024), as well as a material reversal of legal reserves related to talc litigation.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Revenue | $23.74 Billion | $22.45 Billion | $45.64 Billion | $43.83 Billion |
| Net Earnings | $5.54 Billion | $4.69 Billion | $16.54 Billion | $7.94 Billion |
| Diluted EPS | $2.29 | $1.93 | $6.82 | $3.27 |
| Gross Margin | 67.9% | 69.4% | 67.2% | 69.5% |
| Operating Cash Flow (6mo) | $8.05 Billion (vs. $9.29 Billion prior year) | |||
| Total Debt | $50.76 Billion (Current: $11.5B; Long-term: $39.2B) | |||
| Cash & Equivalents | $18.58 Billion |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 5.8% in Q2 and 4.1% for the six months. Growth was driven by acquisitions (Intra-Cellular and Shockwave) and strong performance in Oncology (Darzalex, Carvykti) and Neuroscience (Spravato), partially offset by a 42.7% decline in Stelara sales due to biosimilar competition.
- Profitability Surge: Net earnings for the six months more than doubled to $16.54 billion. This was primarily driven by a $7.0 billion reversal of previously accrued talc litigation reserves following the dismissal of a bankruptcy case in Texas. Excluding this reversal, earnings growth was modest.
- Segment Performance:
- Innovative Medicine: Sales up 4.9% (Q2) and 3.6% (6mo). Oncology grew 24.0% (Q2), while Immunology declined 15.4% (Q2) due to Stelara.
- MedTech: Sales up 7.3% (Q2) and 5.0% (6mo). Cardiovascular sales surged 23.5% (Q2) driven by the Shockwave acquisition.
- Balance Sheet: Total debt increased to $50.8 billion from $41.5 billion a year ago, reflecting $9.2 billion in new debt issuance to fund the Intra-Cellular acquisition. Cash and equivalents decreased to $18.6 billion.
Guidance, Outlook, and Risks
- Legal Contingencies (Talc): Following the dismissal of the Red River bankruptcy case, the Company reversed $7.0 billion in reserves. The remaining talc reserve is approximately $4.0 billion. The Company has returned to the tort system to litigate claims, with bellwether trials scheduled for late 2025 and early 2026.
- Legal Contingencies (Opioids): Approximately 80% of the $5.0 billion state settlement has been paid. Remaining litigation includes government entities and private plaintiffs.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 increases the statutory tax rate on foreign earnings. The Company estimates a one-time re-measurement cost of approximately $1.0 billion to be recorded in Q3 2025.
- Restructuring: The Company initiated a restructuring program for its Surgery franchise (estimated cost $0.9B-$1.0B) and continues the Orthopaedics restructuring (estimated total cost $0.7B-$0.8B).
- Patent Expirations: Continued pressure from biosimilars (Stelara) and generics (Imbruvica, Zyntiga) remains a key risk to revenue stability.
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the remaining $4.0 billion reserve given the return to the tort system and upcoming bellwether trials.
- Stelara Decline Trajectory: Monitor the rate of sales erosion for Stelara as biosimilar launches continue in the U.S. and Europe throughout 2025.
- Acquisition Integration: Assess the revenue contribution and integration costs of the Intra-Cellular Therapies (CAPLYTA) and Shockwave Medical acquisitions.
- Tax Impact: Confirm the final impact of the OBBBA legislation on the Q3 2025 tax provision and future effective tax rates.
- Debt Servicing: Review the impact of higher interest rates on the increased debt load ($50.8B) and future interest expense.